Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 10CNS 3Tumor-Agnostic 2Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Glioma 2Glioblastoma 2

Interventions

Temozolomide 623Radiotherapy 411Bevacizumab 257Magnetic Resonance Spectroscopy 227Cyclophosphamide 179Radiosurgery 163Carboplatin 160Etoposide 132Radiation 129Vincristine 115Irinotecan 115Cisplatin 103Filgrastim 100Specimen Handling 90Nivolumab 88pembrolizumab 84Surgical Procedures, Operative 83Lomustine 82Topotecan 73Doxorubicin 61Melphalan 59Carmustine 57Radiotherapy, Intensity-Modulated 56sargramostim 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 51Chemotherapy, Adjuvant 51Blood Specimen Collection 51Erlotinib Hydrochloride 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
LY-2157299 × CNS × Clear all
NCT01582269 2025-11-24

A Study in Recurrent Glioblastoma (GB)

Eli Lilly and Company

Phase 2 Completed
158 enrolled 20 charts
CNS

Glioblastoma

NCT01682187 2024-11-07

A Dose-Escalation Study in Participants With Recurrent Malignant Glioma

Eli Lilly and Company

Phase 1 Completed
66 enrolled
CNS

Glioma

NCT01220271 2017-02-16

A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

Eli Lilly and Company

Phase 1/2 Completed
75 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡